Quick Answer
Liminatus Pharma, Inc. reported Operating Income of -$2.97 million for fiscal year 2025.
Liminatus Pharma, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$2.97M | +10.9% |
| 2024 | -$3.33M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$701.2K | -29.1% | +37.3% |
| June 30, 2025 | -$1.12M | -23.0% | -438414.1% |
| March 31, 2025 | -$255.00 | -3.2% | +100.0% |
| September 30, 2024 | -$543.1K | — | +40.3% |
| June 30, 2024 | -$909.2K | — | -368004.5% |
| March 31, 2024 | -$247.00 | — | — |
- Liminatus Pharma, Inc. showed an increase of +10.9% in Operating Income compared to the prior fiscal year.
- Over the 2024–2025 period, Liminatus Pharma, Inc.’s operating income has grown by 10.9% (from -$3.33 million to -$2.97 million).
- The most recent figure is from Liminatus Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: